In the Claims:

Please cancel claim 1, without disclaimer or prejudice to the inclusion of the subject matter contained therein in any later filed continuation or divisional application(s). Further, please amend claims 2-4 and add claim 25 as set forth below.

1 (Canceled).

2. (Currently Amended) ~~The composition of claim 1~~A composition comprising a peptide consisting of the amino acid sequence $X_1X_2X_3X_4X_5X_6X_7X_8$, wherein:
X_1 is hydrogen or an amino-terminal blocking group;
X_2 is an amino acid selected from the group consisting of D, E, and R;
X_3 is an amino acid selected from the group consisting of D and E;
X_4 is I;
X_5 is I;
X_6 is M;
X_7 is an amino acid selected from the group consisting of D and E; and
X_8 is hydrogen or a carboxyl-terminal blocking group.

3. (Currently Amended) ~~The composition of claim 1~~A composition comprising a peptide consisting of the amino acid sequence $X_1X_2X_3X_4X_5X_6X_7X_8$, wherein:
X_1 is hydrogen;
X_2 is E;
X_3 is E;
X_4 is I;
X_5 is I;
X_6 is M;
X_7 is D; and
X_8 is hydrogen.

4. (Currently Amended) The composition of claim [[1]] 2, further comprising a pharmaceutically acceptable carrier.

Claims 5-10 (Canceled).

11. (Withdrawn) A method of promoting clearance of scuPA from the surface of a mammalian cell, the method comprising administering the composition of claim 1 to the cell in an amount to promote clearance of the scuPA from the cell.

12. (Withdrawn) The method of claim 11, wherein the cell is a human cell.

13. (Withdrawn) The method of claim 12, wherein the composition is administered *in vivo* in the human.

14. (Withdrawn) A method of impeding pathological migration of a cell in a mammal, the method comprising administering to the mammal the composition of claim 1 in an amount effective to impede pathological migration of the cell.

15. (Withdrawn) The method of claim 14, wherein the composition is administered to the mammal at the site of a tumor in the mammal.

16. (Withdrawn) The method of claim 14, wherein the mammal is a human.

Claims 17-19 (Canceled).

20. (Previously Presented) A kit comprising a peptide having the amino acid sequence $X_1X_2X_3X_4X_5X_6X_7X_8$, wherein:
X_1 is hydrogen, an amino-terminal blocking group, or one to twenty amino acid residues;
X_2 is an amino acid selected from the group consisting of D, E, H, K, and R;
X_3 is an amino acid selected from the group consisting of E and D;
X_4 is an amino acid selected from the group consisting of I, L, and V;
X_5 is an amino acid selected from the group consisting of I, L, and V;
X_6 is an amino acid selected from the group consisting of M;
X_7 is an amino acid selected from the group consisting of D, E, H, K, and R; and
X_8 is hydrogen, a carboxyl-terminal blocking group, or one to twenty amino acid residues, and an instructional material for using the kit.

21. (Withdrawn) A composition comprising a combination of a peptide having the amino acid sequence $X_1X_2X_3X_4X_5X_6X_7X_8$, wherein:
X_1 is hydrogen, an amino-terminal blocking group, or one to twenty amino acid residues;
X_2 is an amino acid selected from the group consisting of D, E, H, K, and R;
X_3 is an amino acid selected from the group consisting of E and D;
X_4 is an amino acid selected from the group consisting of I, L, and V;
X_5 is an amino acid selected from the group consisting of I, L, and V;
X_6 is an amino acid selected from the group consisting of M;
X_7 is an amino acid selected from the group consisting of D, E, H, K, and R; and
X_8 is hydrogen, a carboxyl-terminal blocking group, or one to twenty amino acid residues, and a thrombolytic agent.

22. (Withdrawn) The composition of claim 21, wherein the thrombolytic agent is selected from the group consisting of tissue plasminogen activator, streptokinase, urokinase, the streptokinase derivative and staphylokinase.

23. (Withdrawn) A composition comprising a combination of a peptide having the amino acid sequence $X_1X_2X_3X_4X_5X_6X_7X_8$, wherein:
X_1 is hydrogen, an amino-terminal blocking group, or one to twenty amino acid residues;
X_2 is an amino acid selected from the group consisting of D, E, H, K, and R;
X_3 is an amino acid selected from the group consisting of E and D;
X_4 is an amino acid selected from the group consisting of I, L, and V;
X_5 is an amino acid selected from the group consisting of I, L, and V;

X_6 is an amino acid selected from the group consisting of M;
X_7 is an amino acid selected from the group consisting of D, E, H, K, and R; and
X_8 is hydrogen, a carboxyl-terminal blocking group, or one to twenty amino acid residues, and an anti-coagulating agent.

24. (Withdrawn) The composition of claim 23, wherein the anti-coagulating agent is selected from the group consisting of an agent which inhibits platelet function, and agent which inhibits the activity of thrombin, and agent which promotes the activity of activated protein kinase C, an anti-thrombin III agent, and a tissue factor pathway inhibitor.

25. (New) The composition of claim 3, further comprising a pharmaceutically acceptable carrier.